Extracellular cGAMP transmission drives localized neuroinflammation by activating the STING pathway specifically in microglia positioned within the demyelinated lesion rims of multiple sclerosis brains, rather than acting uniformly across the parenchyma.

This discovery has a Claude-generated validation package with a full experimental design.

Precise Hypothesis

Spine & Adversarial ReadReady for validation

“Extracellular cGAMP concentration and STING pathway activation in microglia are spatially elevated and functionally dependent on local transport specifically within the demyelinated lesion rim relative to lesion core and normal-appearing white matter in MS brain tissue.”

• highThe hypothesis conflates correlation (ISG signature co-localizing with rim microglia) with a specific causal mechanism (extracellular cGAMP transmission via SLC19A1) — type-I IFN signatures in rim microglia are already well documented and could arise from many alternative triggers (mtDNA/TLR9, oxidative-stress-induced cGAS activation intrinsic to microglia themselves, or cytokine paracrine signaling) without requiring intercellular cGAMP transfer.
  The protocol's Arm C (STING antagonist + SLC19A1 blockade dependence test) is designed precisely to isolate transport-dependence from intrinsic cGAS activation; however, the EVP as written does not include a direct cGAS-knockout-in-microglia control arm to rule out microglia-intrinsic cGAS activation as a competing explanation — this is a gap that should be added (microglial cGAS-KO ± conditioned media) before claims of 'transmission' rather than 'intrinsic activation' can be made.
• mediumWhy spatial transcriptomics + LC-MS/MS + ex vivo microglia culture specifically, rather than simpler/cheaper alternatives (e.g., bulk qPCR on microdissected zones, or single STING reporter in vivo imaging)? The methodology choice needs explicit justification against cost and complexity.
  Spatial transcriptomics is justified because the central claim is explicitly about sub-lesion spatial restriction (not just rim-vs-NAWM bulk difference, which prior bulk RNA-seq already partially shows) — only spatially resolved methods can test the specific ≤150µm halo claim and bivariate co-localization with a diffusible metabolite. LC-MS/MS is necessary because no antibody-based proxy reliably quantifies cGAMP itself (IHC/IF only detects pathway activation, not the ligand). This justification should be stated explicitly in any grant/protocol submission to preempt reviewer pushback; it is not currently resolved for the cheaper single-plex IHC-only alternative, which remains a valid fallback if budget constraints force MVT reduction.
• highPost-mortem/autopsy tissue cannot establish temporal causality (does STING activation precede, cause, or follow demyelination?) — a purely cross-sectional human tissue design, even with strong spatial correlation, cannot distinguish cause from consequence of the lesion rim's chronic inflammatory state.
  Acknowledged explicitly in Methodology step 9 (optional in vivo causal extension in EAE/cuprizone models) and reflected in boundary conditions — the core EVP as scoped (MVT, $185K) only establishes spatial correlation and ex vivo pharmacological dependence, not full in vivo causality; the $650K full package is required to approach causal proof, and even then animal demyelination models imperfectly recapitulate human CA-rim biology (iron-rim pathology is not well-reproduced in rodent models), leaving a residual translational gap that this EVP does not fully close.

Experimental Protocol

ROI Projection

Prerequisites

These must be validated before this hypothesis can be confirmed:

• none — this is a foundational/standalone spatial mechanism hypothesis; does not require prior validation of ZNF740/BRD3/CTSS target hierarchy, though CTSS (microglial/myeloid lysosomal protease, MBP cleavage) mechanistic overlap should be cross-checked opportunistically

Implementation Sketch

# Pseudocode: spatial cGAMP-STING validation pipeline

for donor in cohort:
    sections = serial_section(donor.block, n=6)
    rim_mask = segment_rim(sections.iron_stain, sections.IHC_TMEM119)
    zones = {rim: 0-150um, peri_rim: 150-500um, core: >500um, nawm: matched_control}

    spatial_adata = run_visium_or_xenium(sections[0], panel=STING_ISG_microglia_genes)
    spatial_adata.obs['zone'] = assign_zone(spatial_adata.coords, rim_mask)
    isg_score = score_genesets(spatial_adata, geneset=ISG_SIGNATURE)

    ihc_img = run_IF(sections[1], markers=[cGAS, pSTING, pTBK1, IBA1])
    pSTING_density = quantify_HALO(ihc_img, stratify_by=zones)

    lcm_samples = laser_capture_microdissect(sections[2:4], zones)
    cgamp_conc = LCMS_quantify(lcm_samples, standard=synthetic_2'3'_cGAMP)

    donor_result = {
        'isg_by_zone': isg_score.groupby(zone).mean(),
        'pSTING_by_zone': pSTING_density,
        'cgamp_by_zone': cgamp_conc,
    }
    cohort_results.append(donor_result)

# mixed model
model = lmer("isg_score ~ distance_to_rim + cgamp_conc + CD45_density + (1|donor)")
spatial_corr = bivariate_moran(cgamp_conc_map, pSTING_density_map)

# functional arm
conditioned_media = collect_media(rim_astrocyte_culture)
microglia_wt, microglia_STINGko = culture_pairs(iPSC_microglia_line)
for condition in [vehicle, conditioned_media, conditioned_media+H151, recomb_cGAMP]:
    isg_induction = qPCR(microglia_wt, condition) vs qPCR(microglia_STINGko, condition)
    assert_STING_dependence(isg_induction)